Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626818 | 0.83 | ADRA1D (0.61) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL2626822 | 0.78 | HRH3 (0.55) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL2626804 | 0.78 | DAO (0.50) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL4403574 | 0.77 | ADRA1D (0.61) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL2626847 | 0.76 | ADRA2A (0.49) | ADRA1DADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL22287928 | 0.76 | MPO (0.41) | TAAR1 | |
| SCHEMBL632802 | 0.75 | ADRA2C (0.57) | ADRA1DADRA2CADRA1AADRA1BTAAR1 | |
| SCHEMBL16016404 | 0.73 | HRH1 (0.40) | TAAR1HRH4CYP3A4SMN1; SMN2 | |
| SCHEMBL2741597 | 0.72 | TAAR1 (0.59) | HRH3TAAR1HRH4CYP3A4 | |
| SCHEMBL2874845 | 0.72 | ADRA1D (0.47) | ADRA1DADRA2AADRA2BADRA2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196911-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196911-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8178571-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178571-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178571-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100298395-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298395-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298395-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7795292-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795292-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795292-B2 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1797044-A2 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | Allergan, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006036512-A2 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ALLERGAN, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069142-A1 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ALLERGAN, INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069142-A1 | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same | ADRB2, ADRB1, ADRA2C | ADRA1D 9/4885ADRA2A 4/4885ADRA2B 6/4885 |
| US-20100298395-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRA1D 9/4885ADRA2A 4/4885ADRA2B 6/4885 |
| US-20120196911-A1 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRA1D 9/4885ADRA2A 4/4885ADRA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.